Sustained virologic response to standard interferon or pegylated interferon and ribavirin in patients with hepatitis C virus genotype 5: systematic review and meta-analysis of ten studies and 423 patients
| Autor: | Brittany E. Yee, David Jencks, Mindie H. Nguyen, Pardha Devaki |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
Combination therapy Hepatitis C virus Hepacivirus medicine.disease_cause Antiviral Agents Gastroenterology chemistry.chemical_compound Pegylated interferon Internal medicine Ribavirin medicine Humans Hepatology business.industry virus diseases Publication bias Hepatitis C medicine.disease Virology digestive system diseases chemistry Meta-analysis Drug Therapy Combination Interferons business Viral load medicine.drug |
| Zdroj: | Hepatology International. 9:431-437 |
| ISSN: | 1936-0541 1936-0533 |
| Popis: | Interferon (IFN)-free therapy has vastly improved therapeutic options for those with hepatitis C virus infection (HCV). However, the lack of data and the expense limit its use for lesser known genotypes such as HCV-5, especially in countries with financial limitations. Previous reports estimate sustained virologic response (SVR) rates in HCV-5 to be ~40–70 %. Our goal was to estimate pooled SVR rates for HCV-5 treatment-naive patients treated with IFN or peginterferon (PEG IFN) and ribavirin (RBV) combination therapy for 48 weeks. We conducted a literature search to identify articles with HCV-5 patients treated with IFN/PEG IFN + RBV. Pooled SVR rates were reported by random effects modeling with 95 % confidence intervals. Heterogeneity was defined by the Cochrane Q-statistic p ≤ 0.05 and I 2 statistic ≥50 %. A total of 423 patients from ten studies were included in the analysis. The pooled SVR rate for HCV-5 patients treated with IFN/PEG IFN + RBV for 48 weeks was 58.0 % (CI 53.1 %–62.7 %). There was no evidence of heterogeneity (I 2 = 0, p = 0.61) or publication bias (Egger’s test = 0.26). Pooled analysis of HCV-5 patients treated with PEG IFN + RBV was 55.0 % (CI 49.4–61.5 %). There was no evidence of heterogeneity (I 2 = 0.00, p = 0.75) or publication bias (Egger’s test = 0.71). Combination therapy with IFN/PEG IFN + RBV had a pooled EVR of 90.2 % (CI 76.8–96.2 %). SVR for HCV-5 treated with combination therapy (IFN/PEG-IFN + RBV for 48 weeks) was approximately 60 %. Current data are insufficient to evaluate variable duration of treatment (24 vs. 48 weeks), presence or absence of cirrhosis, effects of high versus low viral loads, or degree of fibrosis. The optimal treatment duration for HCV-5 patients with IFN-based combination remains to be established. Data and drug access are needed for treatment for HCV-5 in more resource-limited areas. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink